Paper Details

  1. Home
  2. Paper Details

Hepatotoxicity with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer patients: A network meta-analysis.

Author: ChenSuhua, DuXin, WuYibo, WuZiyang, XieXiaohui

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

A network meta-analysis compared the hepatotoxicity of different EGFR-TKIs used for non-small-cell lung cancer (NSCLC). The analysis found that erlotinib was associated with lower hepatotoxicity compared to other EGFR-TKIs, including gefitinib, afatinib, and osimertinib.
Paper Details　
Original Abstract of the Article :
The efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in patients diagnosed with non-small-cell lung cancer (NSCLC) has been confirmed by a large number of studies. However, hepatotoxicity caused by EGFR-TKIs has not been widely investigated. This review compares th...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/jcpt.13281

データ提供：米国国立医学図書館（NLM）

EGFR-TKIs and Liver Health: A Careful Look

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are a class of medications used to treat certain types of cancer. This research aims to assess the hepatotoxicity, or liver damage, associated with different EGFR-TKIs in patients with non-small-cell lung cancer (NSCLC).

The researchers conducted a network meta-analysis, which is a type of statistical analysis that allows them to compare different treatments across multiple studies. They found that hepatotoxicity varied among different EGFR-TKIs. Some drugs were associated with a higher risk of liver damage than others.

Navigating the Desert of Side Effects

This research highlights the importance of carefully monitoring liver function in patients taking EGFR-TKIs, as the risk of hepatotoxicity can vary depending on the specific drug. It's like navigating a desert with different types of sandstorms - some are more intense than others.

Talking to Your Doctor

If you're taking an EGFR-TKI, it's important to discuss any concerns about potential side effects with your doctor. They can monitor your liver function and adjust your treatment plan as needed.

Dr.Camel's Conclusion

This study provides valuable insights into the potential risks and benefits of different EGFR-TKIs in treating NSCLC. It emphasizes the need for close monitoring of liver function and personalized treatment plans to minimize the risk of hepatotoxicity.

Date :
  1. Date Completed 2021-10-26
  2. Date Revised 2021-10-26
Further Info :

Pubmed ID

33031574

DOI: Digital Object Identifier

10.1111/jcpt.13281

Related Literature

Article Analysis
・Effects of dacomitinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.